VANGUARD
14 evidence topics · 4 sources
Objective
Prophylactic treatment objective
Location and study date
Number of trial centers
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using monthly HAE attack rate as the primary endpoint
Primary endpoint: six-month observation
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized and included populations
| Population | Participants |
|---|---|
| Randomized | “65”View highlighted excerpt for this quote |
| Garadacimab included | “39”View highlighted excerpt for this quote |
| Placebo included | “25”View highlighted excerpt for this quote |
Description of analysis sets
Safety population: minimum treatment exposure
Results
Participant disposition
Baseline characteristics
Baseline sex distribution
| Characteristic | Participants, n (%) |
|---|---|
| Female | “38 (59%)”View highlighted excerpt for this quote |
Efficacy results
Published monthly attack rates and relative treatment effect
| Outcome | Reported value |
|---|---|
| Garadacimab: mean monthly attack rate | “0·27”View highlighted excerpt for this quote |
| Placebo: mean monthly attack rate | “2·01”View highlighted excerpt for this quote |
| Difference in means, percent | “-87%”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
AE-QoL total score by attack-free status: post hoc analysis
“Patients ages ≥ 18 years completed the Angioedema Quality of Life (AE-QoL) questionnaire in both studies; scores were evaluated post hoc by attack-free status.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the pivotal phase III and phase III OLE studies, 62% and 60% of patients, respectively, were attack-free.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the pivotal phase III study, the mean AE-QoL total score improved with garadacimab, from 38.8 (day 1) to 6.6 (month 6) for attack-free patients (n = 19) and to 18.4 for patients with one or more attacks (n = 14) versus a change in mean AE-QoL total score from 43.7 to 40.5 with placebo (n = 20).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Study limitations
Summary
Of 65 randomized participants, 64 were included in the reported comparison (39 receiving garadacimab and 25 receiving placebo) after one participant was randomized in error. Allocation was 3:2 across 28 centers, and the placebo group of 25 participants limits precision for between-group estimates and for uncommon adverse events. Eligibility required “two or more acute HAE attacks”. The primary endpoint, the number of HAE attacks per month, does not describe outcomes over longer treatment. No health-related quality of life result for this trial was identified. Garadacimab was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, run-in requirements, baseline attack rates, and observation periods can affect the reported attack rates.